1.	Study of Breast Cancer Prevention by Letrozole in High Risk Women Phase: Phase II Type: Prevention Status: Active Age: 30 to 69 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 10587, CFEM345AUS45, 5R01CA122577-03, NCT00579826
2.	Green Tea and Reduction of Breast Cancer Risk Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 50 to 64 Sponsor: NCI, Other Protocol IDs: 0806M36121, NCT00917735
3.	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 50 Sponsor: NCI, Other Protocol IDs: CDR0000668698, S0812, U10CA032102, SWOG-S0812, NCT01097278
4.	Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 25 and over Sponsor: NCI, Other Protocol IDs: 08218, R01CA140245-01, NCI-2010-01976, NCT01196936
5.	Letrozole in Treating Healthy Postmenopausal Women at High Risk for Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: NCI-2013-00757, 09-0869-04, N01CN35158, UARIZ-09-0869-04, UARIZ-UAZ08-12-02, NCT01077453
6.	Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: IUCRO-0365, NCI-2013-00422, NCT01793948